Consistent with our observations from U87 glioblastoma cells, the control U118 cells showed more sensitivity to TMZ treatment compared the ADAR3-expressing U118 cells across the entire concentration range (200–500 μM) with the most significant growth differences occurring at 400 and 500 μM treatment for 24 h (Supplementary Fig. S5b) and 300–500 μM treatment for 48 h (Fig. 5b). The gene discussed is ADARB2; the disease is glioblastoma.